Ipsen has presented long-awaited phase three results for elafibranor, a new class of medication for Primary Biliary Cholangitis. The disease, a genetic chronic liver condition, primarily affects women. Symptoms, which can take years to present, include fatigue and joint pain. Ipsen’s Jennifer Schranz noted that 51% of patients involved in the ELATIVE trial experienced significant benefits compared to 4% taking a placebo.
Critical Vulnerabilities in Mitel SIP Phones Let Attackers Inject Malicious Commands
Researchers found severe vulnerabilities in Mitel’s SIP phones, notably CVE-2025-47188, a critical command injection flaw with a CVSS score of 9.8, affecting 6800, 6900, and
